Amarin | AMRN - Selling And Administration Expenses

Stock Price
14.89
Daily Change
-0.11 -0.73%
Monthly
10.26%
Yearly
34.71%
Q1 Forecast
14.47

Amarin reported $17.94M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Amarin USD 17.94M 17.86M Sep/2025
AstraZeneca USD 148M 4.86B Sep/2025
DBV Technologies USD 3.63M 3.18M Sep/2025
GlaxoSmithKline GBP 2.16B 19M Sep/2025
Halozyme Therapeutics USD 37.53M 4.53M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Neurocrine Biosciences USD 291.6M 5.3M Sep/2025
Novartis USD 3.31B 134M Sep/2025